Serum Omentin-1 Research Articles

Role of omentin 1 and IL-6 in type 2 diabetes mellitus patients with diabetic retinopathy

The study included 60 diabetic patients (30 patients type 2 diabetes mellitus complicated with diabetic retinopathy (DR) and 30 patients T2DM not complicated with DR). The study also included 30 healthy control individuals defended as subjects who apparently haven’t any chronic diseases. investigations were done including IL-6 and serum omentin-1. Fundus examination was carried out by an expert ophthalmologist. The study showed that the lowest mean of serum omentin-1 was recorded (P<0.05) in DR patients (687 pg/ml), and the highest (P<0.05)was in the control group (3540.625 pg/ml), The study also demonstrated that there was a significant decrease (P<0.05) in DM patients (991.2 pg/ml). The study also showed that serum IL-6 was increased significantly(P<0.05) in DR patients (253.7 pg/ml) as compared with the control group (35.33 pg/ml), The study also showed that serum IL-6 was increased significantly (P<0.05) in DM patients (102.5 pg/ml). The study showed negative correlation of serum omentin-1 concentrations with IL-6 in DR patients.

Relationship of omentin-1 with oxidative stress in Iraqi patients with myocardial infraction

A recently recognized adipokine mediator omentin-1 mainly expressed in human epicardial adipose tissue (EAT) has been found to inhibit the inflammatory response and atherosclerosis factors that has potential beneficial effects on cardiovascular disorders. Recent clinical studies reported that the serum omentin-1 levels were negatively related to the severity of Ischemic heart diseases. In this study, we characterized the clinical significance of omentin-1 in myocardial infarction (MI) patients.Investigated its association with oxidative stress, and demonstrated its protective effect as an antioxidant. The study contained 120 subjects who were divided evenly into patients and control groups for the period between September and December 2021. The serum levels of omentin-1 were assessed by enzyme-linked immunosorbent assays methods and serum zinc and copper were measured using atomic absorption spectroscopy. Also, protein oxidation markers and malondialdehyde (MDA) serum levels were measured by spectrophotometer.

Aerobic Exercise Training Effects on Omentin-1, Insulin Resistance, and Lipid Profile Among Male Smokers

ABSTRACT Background: Omentin-1 is a circulating adipokine that can serve as a biomarker for assessment of metabolic risk factors. We investigated the effect of eight weeks of aerobic exercise training on serum omentin-1, insulin resistance and lipid profile in nonsmokers and smokers. Methods: Nineteen male nonsmokers (aged 27.88 ± 2.47 years, and with BMI of 22.69 ± 1.77 kg.m−2) and twenty male smokers (aged 30.11 ± 1.96 years, and with BMI of 23.12 ± 1.91 kg.m−2) were randomly assigned into nonsmokers control group (C), nonsmokers exercise group (E), control smoker group (CS), and exercise smoker group (ES). Exercise groups participated in an eight-week aerobic exercise training program (three times a week, 20–35 min per session at 55%-70% of maximum heart rate). Serum omentin-1 and insulin values were determined by ELISA. The Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), glucose level and lipid profile were measured before and after the intervention. Pearson correlation test, Eta test, paired samples t-test, one and two-way analysis of variance (ANOVA) and post-hoc Tukey test were applied for data analysis (p < .05). Results: Aerobic exercise improved both serum omentin-1 and high lipoprotein cholesterol (HDL-C) in the exercise groups (P < .05). Also, exercise training reduced insulin, glucose, HOMA-IR, triglyceride (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels (p < .05). Omentin-1 was significantly correlated with glucose, insulin, HOMA-IR, TG, TC, LDL-C and HDL-C in both nonsmokers and smokers. Conclusions: The findings suggest that aerobic exercise-induced changes in omentin-1 in the exercise-trained groups may be associated with the beneficial effects of exercise on reduced insulin resistance and lipid profile.

Association between Serum Omentin-1 Level and Insulin Resistance, Hematological Factors and Gestational Age in Preterm Newborn

Association between Serum Omentin-1 Level and Insulin Resistance, Hematological Factors and Gestational Age in Preterm Newborn

Sortilin/Omentin-1 ratio in peripheral artery disease: A cross-sectional study on 295 unselected elderly patients

BackgroundThe role of sortilin and omentin-1 in the pathogenesis of atherosclerosis and vascular disease is an emerging topic in recent years. These molecules can be found circulating in the blood. Recent studies have shown how these biomarkers appear to correlate with the severity of PAD. The levels of these molecules appear to be inversely proportional to each other. Their relationship may provide further insight into the management of the very old diabetic patients with PAD. This study aimed to assess the possible role of sortilin/omentin-1 ratio as easy-to-measure marker in peripheral artery disease (PAD) in type-2 diabetic patients. MethodsThis study analyzed the association between sortilin and omentin-1 serum levels and the presence of clinically significant lower limb PAD in diabetic individuals. We enrolled 295 diabetic patients, including 179 with PAD. Serum levels were collected and correlated with clinical characteristics of the patients. ResultsSortilin concentration was significantly higher in the latter group compared to the former and there was a trend toward increased sortilin levels as disease severity increased. Omentin-1 serum levels were significantly lower in diabetic patients with PAD than in diabetic controls and the levels gradually decreased in proportion to disease severity. The ratio of sortilin to omentin-1 was significantly higher in patients with PAD compared to the other group. ConclusionThe sortilin to omentin-1 ratio appears to be a predictive factor for PAD in patients with type-2 diabetes and it may be a promising marker for clinically significant atherosclerosis of the lower limbs. Further studies are needed to confirm this finding and to evaluate its clinical usefulness.

A Randomized Trial with Two Hypocaloric Diets with Different Lipid Profiles and Effects on Serum Omentin-1 Levels in Obese Subjects

Background The effects of weight loss therapies on omentin-1 levels have been unclear, showing both elevations and decreases in circulating levels. The role of dietary fat might have an important role. The aim of our investigation was to evaluate the influence of weight decrease on omentin-1 levels after two different high-fat hypocaloric diets. Methods 319 Caucasian obese subjects were randomly allocated during 12 weeks (Diet M (high monounsaturated fat diet) vs. Diet P (high polyunsaturated fat diet)). The mean age was 47.2 ± 5.0 years (range: 26-64), and the mean body mass index (BMI) was 37.9 ± 4.1 kg/m2 (range: 30.6-39.8). Sex distribution was 237 females (74.7%) and 72 males (25.3%). Anthropometric and biochemical parameters were evaluated at basal and after both diets. SPSS 23.0 has been used to realize univariant and multivariant statistical analysis. Results After both diets, BMI, weight, fat mass, waist circumference, systolic blood, LDL-cholesterol, insulin levels, and HOMA-IR decreased in a statistical way from basal values. These improvements were similar in both diets. After Diet P, omentin-1 levels increase (21.2 ± 9.1 ng/ml: P = 0.02), and after Diet M, this adipokine increases (47.1 ± 11.2 ng/ml: P = 0.02), too. The increase of omentin-1 with Diet M was statistically significantly higher than that after Diet P (P = 0.01). A multiple regression analyses adjusted by age and sex reported a statistical relation between BMI (kg/m2) and insulin (UI/L) with omentin-1 levels. Conclusions Our study demonstrated a significant improvement on serum omentin-1 levels after weight loss secondary to both diets; in contrast, omentin-1 improvement was higher with Diet M than with Diet P.

Analysing adipokine Omentin-1 in periodontal disease and type-2 diabetes mellitus: An interventional comparative study

Background and objectiveOmentin-1 is an anti-inflammatory adipokine associated with metabolic disorders including insulin resistance, glucose intolerance and type 2 diabetes mellitus (T2DM). Diabetes is a crucial systemic risk factor for occurrence of periodontitis. Periodontitis is deliberated as a complication of diabetes. This study aimed to estimate salivary and serum levels of Omentin-1 in chronic periodontitis with or without diabetes mellitus before and after scaling and root planing (SRP) and also the level of glycemic control. Materials and methodsBased on history and clinical parameters, 70 subjects were allocated into two groups i.e. chronic periodontitis (Group 1) and chronic periodontitis with well controlled T2DM (Group 2). Baseline saliva and serum samples were collected from both groups followed by full mouth SRP. Subjects were recalled 3 months post SRP for salivary and serum sample collection and measurement of clinical parameters. Serum as well as salivary samples collected were further analysed using enzyme-linked immunosorbent assay to determine the Omentin-1 concentration in each sample. ResultsThe levels of Omentin-1 in saliva and serum were significantly lower in both the groups at baseline. Clinical parameters exhibited a significant reduction 3 months post SRP in both groups. Salivary and serum Omentin-1 levels significantly increased in both the groups, 3 months post SRP. HbA1c levels also reduced significantly post therapy. ConclusionA significant relation exists between salivary and serum Omentin-1 in chronic periodontitis and chronic periodontitis with T2DM. In consequence, Omentin-1 level can have possible application as inflammatory marker of T2DM, periodontal disease and treatment outcome.

Analysis of Changes in Serum Levels and Gene Expression Profiles of Novel Adipocytokines (Omentin, Vaspin, Irisin and Visfatin) and Their Correlation with Serum C-reactive Protein Levels in Women Diagnosed with Endometriosis

This study aimed to investigate the role of new adipocytokines (omentin, vaspin, irisin and visfatin) in the development of endometriosis and the relationship of these adipocytokines with the inflammatory marker, C-reactive protein (CRP) levels in serum. In this study, endometriosis (n=16) and control groups (n=14) were determined via ultrasound. Serum omentin, vaspin and irisin levels were measured by ELISA method. CRP levels in serum and the gene expression of visfatin and vaspin in whole blood samples were determined by clinical analyzer and the real-time polymerase chain reaction, respectively. Serum irisin and CRP levels in the endometriosis group were significantly higher than in the control group. Irisin protein levels demonstrated a positive correlation with body mass index and CRP in women diagnosed with endometriosis. No statistically significant difference was found in serum omentin and vaspin levels between groups. The visfatin and vaspin gene expression in whole blood samples from the endometriosis group was found to be significantly lower than the control group. Increased levels of serum irisin and decreased visfatin and vaspin gene expressions in blood may be considered as a potential biomarker in endometriosis. The identification of new adipocytokines, which demonstrate an alteration in the presence of endometriosis and the relationship between these adipocytokines and inflammation will facilitate the detection of mechanisms involved in endometriosis and will lead to the development of targeted therapy.

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females.

Osteoporosis is a condition in which bone mineral density is reduced due to altered bone microstructure, which results in increased skeletal fragility and incidence of various types of fractures. Adipokines such as chemerin, vaspin, omentin-1 and osteoprotegerin are involved in bone remodeling. The current study was designed to determine the changes in circulating chemerin, vaspin, omentin-1, and osteoprotegerin levels after treatment with oral ibandronate 150 mg in postmenopausal osteoporotic females. The present study enrolled 107 postmenopausal osteoporotic females from a tertiary care hospital in Faisalabad, Pakistan, based on stringent inclusion and exclusion criteria. Sixty-six healthy postmenopausal, non-osteoporotic females with no systemic illness were chosen from the general population. The assessment of bone mineral density (BMD) was done using a DEXA scan. Serum levels of chemerin, vaspin, omentin-1 and osteoprotegerin were estimated using commercially available enzyme-linked immunosorbent assay kits. The collected data were analyzed with the Statistical Package for Social Sciences (SPSS) version 24. Following 6 months of ibandronate treatment, there was a significant decrease of 24.24% (p < .033) in serum chemerin levels, as well as a significant increase in serum vaspin levels 343.32% (p < .001) and osteoprotegerin levels 19.57% (p < .001), with no significant change in omentin-1 levels. Thus, an increase in serum chemerin levels and a decrease in serum vaspin and osteoprotegerin levels could be implicated in osteoporosis.

Association of Omentin rs2274907 Gene Polymorphism and Its Protein on the Risk of Obesity and Metabolic Disorder in Thai Children

Omentin is an adipocytokine that expresses in white adipose tissues. It is a marker for preventing the development of pro-inflammatory states related to diseases like obesity. This study aimed to examine the concentrations of omentin and anthropometric-biochemical parameters in obese children and healthy controls. Also, to search for the associations of omentin rs2274907 gene polymorphism with omentin levels and obesity among Thai children. A total of 293 children, 178 obese cases and 115 healthy controls, were recruited for this study. The omentin level was measured using the enzyme- linked immunosorbent assay (ELISA), and genotyping was performed using the polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) method. Serum omentin levels were significantly lower in the obese group than in the control group (13.9 and 25.0 ng/mL, respectively, p &lt; 0.001). The omentin levels had significant negative correlation with body weight, body mass index (BMI) percentile, waist circumference, triglycerides (r = –0.276, –0.275, –0.259, –0.242, p &lt; 0.001), and had positive correlation with high-density lipoprotein cholesterol (HDL-C) levels (r = 0.210, p &lt; 0.001). There was a significant association between obesity and serum omentin levels (p &lt; 0.05). However, the omentin rs2274907 gene polymorphism showed no significant relationship with the omentin levels and obesity among Thai children. These findings in Thai children suggest that omentin level, but not omentin rs2274907 gene polymorphism, may influence susceptibility to obesity.

The Effect of the Ketogenic Diet on Adiponectin, Omentin and Vaspin in Children with Drug-Resistant Epilepsy.

Background: Changes in adipokine secretion may be involved in the anti-epileptic effect of a ketogenic diet (KD) in drug-resistant epilepsy (DRE). Objectives: The assessment of the influence of KD on serum adiponectin, omentin-1, and vaspin in children with DRE. Methods: Anthropometric measurements (weight, height, BMI, and waist-to-hip circumference ratio) were performed in 72 children aged 3–9 years, divided into 3 groups: 24 children with DRE treated with KD, 26—treated with valproic acid (VPA), and a control group of 22 children. Biochemical tests included fasting glucose, insulin, beta-hydroxybutyric acid, lipid profile, aminotransferases activities, and blood gasometry. Serum levels of adiponectin, omentin-1 and vaspin were assayed using commercially available ELISA tests. Results: Serum levels of adiponectin and omentin-1 in the KD group were significantly higher and vaspin—lower in comparison to patients receiving VPA and the control group. In all examined children, serum adiponectin and omentin-1 correlated negatively with WHR and serum triglycerides, insulin, fasting glucose, and HOMA-IR. Vaspin levels correlated negatively with serum triglycerides and positively with body weight, BMI, fasting glucose, insulin, and HOMA-IR. Conclusion: One of the potential mechanisms of KD in children with drug-resistant epilepsy may be a modulation of metabolically beneficial and anti-inflammatory adipokine levels.

Association of vaspin rs2236242 and Val109Asp omentin genes polymorphism and their serum levels with increased risk of breast cancer

Breast cancer represents the leading cause of cancer-related death in women globally. Obesity is one of the risk factors for breast cancer, particularly in postmenopausal women. Adiposopathy causes hypertrophy, which promotes metabolic dysregulation, hypoxia, inflammation, insulin resistance, and altered adipokine production such as vaspin and omentin-1. The objective of this study is to inspect the link between the vaspin rs2236242 and the Val109Asp omentin gene polymorphisms and their serum levels with breast cancer occurrence in postmenopausal females. The gene polymorphisms of vaspin rs2236242 and Val109Asp omentin were identified by T-ARMS-PCR and PCR-RFLP respectively. The glucose homeostasis traits, lipid profile, total antioxidant capacity, and circulating vaspin and omentin-1 levels were all assessed. The AT genotype of vaspin rs2236242 and the Val/Asp genotype of Val109Asp omentin were more prominent in breast cancer patients than the TT and Asp/Asp genotypes respectively. Breast cancer patients showed significant lower levels of serum vaspin and omentin-1. The AT genotype of the vaspin rs2236242 polymorphism, the heterozygous Asp/Val genotype of the omentin-1 gene, and low serum vaspin and omentin-1 levels are more associated with breast cancer incidence. On the flip side, higher levels of serum vaspin and omentin appear to protect against the incidence of breast cancer.

Omentin-1 and diabetic foot.

Introduction: Diabetic foot disease is an advanced complication of diabetes mellitus, which is associated with severe invalidization and high mortality rate among affected people. Many factors are involved in its pathogenesis but not all of them are fully elucidated. Objectives: Adipose tissue and its hormones - adipokines, are related to diabetic complications and metabolic disorders. Until now, there are limited data on their role in diabetic foot. The aim of this cross-sectional study is to determine the levels of the adipokine omentin-1 in people with and without diabetic foot disease and to look for its potential involvement in this complication. Methods: Eighty patients with type 2 diabetes and mean age of 60.8±10.5 years were included in this study. They were divided into two groups: with (n=36) and without (n=44) diabetic foot disease. Standard antrometric, clinical and laboratory tests were made. Body composition was analyzed by bioelectrical impedance based device. Serum omentin-1 was measured using ELISA method. Results: Levels of omentin-1 were significantly higher among people with diabetic foot disease (700.2±345.1 ng/ml), compared to the other group (560.2±176.7 ng/ml). This difference remained significant even after adjusting for potential confounders. In a regression model omentin-1 proved its predictive value for development of diabetic foot. Conclusion: Adipokines, and particularly omentin-1, might be included in the pathogenesis of diabetic foot disease.

The Link between Serum Omentin Level and Insulin Resistance Biomarkers, Lipid Profile, and Atherogenic Indices in Iraqi Obese Patients.

Omentin (or intelectin) is a main visceral fat secretory adipokine. There is a growing interest to link omentin, obesity and co-morbidity factors. The aim of the present study is to evaluate serum omentin and its association to insulin resistance biomarkers, lipid profile and atherogenic indies. This cross – sectional study was conducted in Obesity Research and Therapy Unit-Alkindy College of Medicine by recruiting (115) individuals; 49 males /66 females. Subjects between (20 to 60) years of age were selected and classified into two groups according to their Body mass index (BMI). Group1 involved healthy lean volunteers (25 male/ 36 female; BMI 18.5 - 24.9). Group2 involved obese subjects; (24 male / 36 female with BMI ≥ 30). The study shows that obese group has higher omentin levels compared to the healthy lean group (15.49 ± 4.20 vs. 10.15 ± 5.04 pg/ml, P &lt;0.001). In addition; obese group exhibited significantly higher levels waist circumference (WC), waist to hip ratio (WHR), glucose, insulin, homeostatic module of insulin resistance (HOMA2-IR) and lipid profile and lower levels of HDL-Chol (P &lt;0.05). Omentin levels were significantly and positively correlated with WC, WHR, BMI, glucose, hemoglobin A1c, HOMA2-IR, triglyceride, total cholesterol, low density lipoproteins - cholesterol, triglyceride to glucose index (TyG index) and atherogenic index of plasma (AIP); (P&lt; 0.05). Multiple regression analysis established that omentin levels was found to be associated with glucose, total Chol, TyG index and AIP in total population. These findings indicate that serum omentin levels are higher in obese individuals compared to lean subjects. Furthermore, omentin was linked to insulin resistance biomarkers and other risk factors indices such as AIP and TyG. Omentin can be used as a metabolic marker in obese.

Evaluation of Serum Omentin-1, Vaspin, Leptin, Adiponectin Levels in Obese/Overweight Children and Their Relationship With Non-Alcoholic Fatty Liver Disease.

To investigate adipokines (vaspin, omentin-1, adiponectin and leptin) and their correlation with hepatosteatosis degree in obese/overweight (O/O) children. We analyzed adipokine levels of 81 children (49 O/O, [body mass index (BMI) > 95th] and 32 non-obese (BMI = 5-85th) admitted to the pediatric outpatient clinic. Serum triglyceride, glucose, low density lipoprotein-cholesterol, total cholesterol, high density lipoprotein-cholesterol, alanine aminotransferase, aspartate aminotransferase (AST), insulin, HbA1c levels and leptin, omentin-1, vaspin, adiponectin levels were studied. O/O children with hepatosteatosis were divided into grades 1, 2 and 3 according to the degree of hepatosteatosis determined by ultrasonography. While AST (p = 0.001), triglyceride (p = 0.006), BMI percentile (p = 0.000), HOMA index (p = 0.002), systolic blood pressure (p = 0.02), leptin (p = 0.001), omentin-1 (p = 0.001), adiponectin (p = 0.001) levels were higher, vaspin level was lower (p = 0.008) in the (O/O) group compared to the controls. There was a positive correlation between HDL and vaspin, and a negative correlation between HDL and omentin-1 in the O/O group. Also it was observed that as the degree of hepatosteotosis increased, leptin (p = 0.004), omentin-1 (p = 0.001) levels were increased. There was no significant change in vaspin level (p = 0.128). The high levels of omentin-1, leptin and adiponectin have an association with the development of hepatosteatosis in O/O children.

Serum omentin-1 levels in type II diabetes and its relationship with obesity

Background Diabetes mellitus (DM) is a complex metabolic disorder, and its rapid emergence worldwide has led to its classification as an epidemic. Aim To increase our knowledge about omentin-1 and its relation with type 2 DM, insulin resistance, and obesity. Patients and methods This study included 50 patients with type 2 DM, with an age range from 40 to 70 years, who were divided into two groups (25 obese and 25 nonobese), as well as 40 age group (20 obese and 20 nonobese)-matched patients, who formed the control group. Each group was subjected to full history taking and clinical examination (fasting blood glucose, total cholesterol, triglycerides, low-density lipoprotein-cholesterol, glycosylated hemoglobin, fasting insulin, and serum omentin-1 levels). Weight and height were measured. Homeostasis model assessment insulin resistance and BMI were calculated. Results The study showed a significant decrease in serum omentin-1 levels in type 2 diabetic patients in comparison with the control group. Serum omentin-1 levels inversely correlated with obesity, insulin resistance, and systolic blood pressure. Negative associations were found between serum omentin-1 level and fasting glucose, glycosylated hemoglobin, and fasting lipid levels. Conclusion Omentin-1 may be used as a biomarker for obesity and associated metabolic and vascular disorders.

Omentin-1 Levels in Obesity

Omentin-1 is an anti-inflammatory adipokine secreted by stromal vascular cells. Inflammation and apoptosis of adipocyte tissue in obesity lead to decreased production of omentin-1. This study aims to find the difference in omentin-1 levels in the obese and non-obese groups and the correlation between levels of omentin-1 with BMI and waist circumference. This study was a cross-sectional study involving 70 subjects with 37 people in the obese group and 33 people in the non-obese group. Anthropometric data including weight, height, waist circumference, and BMI were measured. Serum omentin-1 levels were measured by ELISA. The statistical tests used were Chi-square, T-test, Mann-Whitney test, and Spearman test. Test results were significant if p-value &lt; 0.05. Significant difference was observed in serum omentin-1 levels between obese and non-obese group (median 140,31 range (88.08 – 382.76) vs. 210,97 range (124,44–577,96) ng/mL), respectively; p &lt; 0.001). Serum omentin-1 correlated negatively with BMI (p=0.001, r = - 0.398) and waist circumference (p=0.017, r = - 0.286). Obesity causes inflammation and increased death of adipocyte tissues due to apoptosis, autophagy, and fibrosis resulting in decreased production of omentin-1 by stromal vascular cells. Anthropometric parameters of waist circumference and BMI describe the distribution of adipocyte tissue and affect the secretion of omentin-1. Omentin-1 levels in the obese group were lower than in the non-obese group. The higher the BMI and waist circumference, the lower the omentin-1 level.

Relationship between circulating serum omentin-1 levels and nascent metabolic syndrome in patients with hypertension

The prevalence of metabolic syndrome (MetS) is more common in patients with hypertension and is associated with an increased risk of target organ damage and/or cardiovascular disease (CVD). Omentin-1 is...

PEX-168 improves insulin resistance, inflammatory response and adipokines in simple obese mice: a mechanistic exploration

BackgroundPolyethylene glycol loxenatide (PEX-168) is a new antidiabetic drug; as such, there are not yet any reports on its weight loss effect. Therefore, this trial was designed to investigate the effect of PEX-168 on simple obese mice.MethodsThirty healthy male C57BL/6 mice were randomly selected and divided into a control group (NC) and an obesity model group. The high-fat diet-induced simple obesity mice were divided into a model control group (HF) and three intervention groups. The intervention groups were injected with different doses of PEX-168 intraperitoneally once a week for 12 weeks (low (LD), medium (MD) and high (HD)). Fasting blood glucose (FBG), body weight and food intake were measured from 1 to 12 weeks after PEX-168 injection. The serum insulin (INS), C-reactive protein (CRP), chemerin and omentin levels were measured after 12 weeks.ResultsCompared with the HF group, the low dose of PEX-168 reduced the body weight of the mice in a short period of time (8 weeks), and the mice in the MD and HD groups showed a significant decrease in body weight (P < 0.05). The low dose of PEX-168 could effectively improve the blood glucose and homeostasis model assessment of insulin resistance (Homa-IR) of the mice (FBG P < 0.05 INS, Homa-IR P < 0.001), but there was no significant difference between different doses (P > 0.05). CRP levels in the MD and HD groups were significantly improved (P < 0.05). The levels of serum chemerin and omentin in the intervention groups were also significantly improved (P < 0.01), but there was no significant difference between the different doses (P > 0.05).ConclusionsPEX-168 significantly reduced the body weight of simple obese mice and improved the insulin resistance. PEX-168 may regulate the expression of chemerin and omentin through its hypoglycaemic effect, and the weight-reducing effect of PEX-168 is unlikely to be the reason for the changes in both.

Circulating Omentin-1 as a Biomarker at the Intersection of Postmenopausal Breast Cancer Occurrence and Cardiometabolic Risk: An Observational Cross-Sectional Study.

Aberrant circulating omentin-1, which is an anti-inflammatory and pro-apoptotic adipokine, has been reported in various solid tumors. Therefore, we investigated whether circulating omentin-1 could be associated with postmenopausal BC (PBC) and could be used as a potential diagnostic and clinical tool taking into consideration clinicopathologic features, tumor markers, as well as anthropometric, metabolic, and inflammatory parameters. Serum omentin-1, tumor markers (CA15-3 and CEA); metabolic (insulin, glucose, HOMA index, and serum lipids), anthropometric (BMI, waist circumference, and fat mass), and inflammatory (TNF-α, IL-6, hsCRP) parameters; classic adipokines (leptin and adiponectin); the Mediterranean diet (MedDiet) score; and cardiovascular (CVD) risk were determined in 103 postmenopausal women with pathologically confirmed incident invasive BC, 103 controls matched on age, 51 patients with benign breast lesions (BBL), and 50 obese postmenopausal women of similar age. The mean serum omentin-1 was significantly lower in cases than in controls and patients with BBL (p < 0.001). In the patients, omentin-1 was inversely associated with tumor, metabolic and inflammatory biomarkers, cancer stage, and the number of infiltrated lymph nodes (p < 0.05). In all study participants, omentin-1 was negatively correlated with CVD risk and positively correlated with MedDiet score. Lower circulating omentin-1 was independently associated with PBC occurrence above and beyond known risk factors. According to the ROC curve analysis, the overall diagnostic performance of omentin-1 (0.84, 95% CI 0.79–0.89) is similar to CA15-3. Circulating omentin-1 may be a biomarker at the intersection of PBC and cardiometabolic risk in postmenopausal women, and could be modulated by the adoption of a MedDiet. Further mechanistic and large multicentric prospective and longitudinal studies are required to elucidate the ontological role of omentin-1 in BC and CVD risks, as well as its diagnostic and prognostic ability and its therapeutic potential.